DBV Technologies (DBVT) Total Current Liabilities (2015 - 2026)
DBV Technologies (DBVT) posted Total Current Liabilities of $54.3 million for Q2 2026, up 4.83% sequentially from $51.8 million in Q1 2026, and up 9.86% YoY from $49.4 million in Q2 2025.
DBV Technologies (DBVT) Total Current Liabilities (2015 - 2026) Analysis & Trends
DBV Technologies has reported Total Current Liabilities for 12 years, with the latest figure at $54.3 million in Q2 2026.
- Quarterly Total Current Liabilities rose 9.86% year-over-year to $54.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $54.3 million (up 9.86% YoY) and the FY2025 annual result came in at $58.0 million, up 86.28% from the prior year.
- Total Current Liabilities improved to $54.3 million in Q2 2026 per DBVT's latest filing, from $51.8 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $58.0 million in Q4 2025 and troughed at $26.0 million in Q1 2022.
- A 5-year average of $37.1 million and a median of $32.1 million in 2023 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities tumbled 32.96% in 2022, then surged 86.28% in 2025.
- Over 5 years, Total Current Liabilities stood at $29.5 million in 2022, then climbed by 26.48% to $37.3 million in 2023, then dropped by 16.61% to $31.1 million in 2024, then surged by 86.28% to $58.0 million in 2025, then slipped by 6.38% to $54.3 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $54.3 million, $51.8 million, and $58.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | 54.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 54.30 Mn |
| Mar 31, 2026 | 51.80 Mn |
| Dec 31, 2025 | 58.00 Mn |
| Sep 30, 2025 | 49.49 Mn |
| Jun 30, 2025 | 49.43 Mn |
| Mar 31, 2025 | 40.38 Mn |
| Dec 31, 2024 | 31.14 Mn |
| Sep 30, 2024 | 30.91 Mn |
| Jun 30, 2024 | 27.38 Mn |
| Mar 31, 2024 | 26.48 Mn |
| Dec 31, 2023 | 37.34 Mn |
| Sep 30, 2023 | 31.44 Mn |
| Jun 30, 2023 | 33.37 Mn |
| Mar 31, 2023 | 32.78 Mn |
| Dec 31, 2022 | 29.52 Mn |
| Sep 30, 2022 | 28.39 Mn |
| Jun 30, 2022 | 30.43 Mn |
| Mar 31, 2022 | 26.03 Mn |
| Dec 31, 2021 | 31.40 Mn |
| Sep 30, 2021 | 33.81 Mn |